임상 레이더 AI
임상시험 NCT07221890은(는) 자가면역 질환, 류마티스 관절염 (RA), 염증성 장질환 (IBD), Psoriasis (PsO)에 대해 진행중, 모집종료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기

A Trial of Academic Detailing to Promote Prescribing of Biosimilars 1,325 생물학적 제제 학술 주도 비대면

진행중, 모집종료
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07221890은(는) 자가면역 질환, 류마티스 관절염 (RA), 염증성 장질환 (IBD), Psoriasis (PsO)에 대해 알아보는 중재연구입니다. 현재 상태는 진행중, 모집종료이며, 연구는 2025년 11월 6일에 시작되어 1,325명의 참여자를 모집하고 있습니다. 브리검 앤 위민스 병원이(가) 진행하며, 2027년 3월 31일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2025년 12월 8일에 갱신되었습니다.
간단한 개요
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are:

  1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab?
  2. Do in-person or virtual visits work better?

Researchers will compare clinicians...

더 보기
상세한 설명
This is a parallel, cluster randomized controlled trial in which medical practices with clinicians who prescribed adalimumab (Humira) to patients in a Humana Medicare Prescription Drug Plan (PDP) will be randomized to have eligible clinicians within the practice invited to participate in the educational module about biosimilars (the intervention group). Practices with eligible physicians that are not offered the educ...더 보기
공식 제목

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

질환명
자가면역 질환류마티스 관절염 (RA)염증성 장질환 (IBD)Psoriasis (PsO)
기타 연구 식별자
  • 2025P002143
NCT 번호
NCT07221890
실제 연구 시작일
2025-11-06
최신 업데이트 게시
2025-12-08
예상 연구 완료일
2027-03-31
계획된 등록 인원
1,325
연구종류
중재연구
단계/상
해당 없음
상태
진행중, 모집종료
키워드
biosimilar
biologic
academic detailing
clinician education
prescribing
Medicare Part D
주요 목적
건강 서비스 연구
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Intervention
Offered an academic detailing session either in-person or virtually (depending on assigned geographic region), plus standard-of-care outreach from the insurance plan.
Offered an academic detailing session
Clinicians will be offered an academic detailing session that will be delivered by a specially trained pharmacist, nurse, or physician (i.e., detailer). These academic detailers will be provided and trained by an independent non-profit organization. After a clinician agrees to participate in an academic detailing session, the detailer will schedule a 1-on-1 meeting lasting 15-20 minutes during which the detailer will...더 보기
Standard-of-care outreach from the insurance plan
Clinicians will receive formulary information from Humana to provide information about coverage of adalimumab (Humira) and its biosimilars.
활성 대조군Control
Not offered an academic detailing session. Standard-of-care outreach from the insurance plan.
Standard-of-care outreach from the insurance plan
Clinicians will receive formulary information from Humana to provide information about coverage of adalimumab (Humira) and its biosimilars.
주요결과변수
결과변수측정값 설명시간 범위
Number of biosimilar adalimumab prescriptions per clinician
12 months
Number of originator adalimumab (Humira) prescriptions per clinician
12 months
Total spending (payer + patient) on adalimumab
12 months
Patient out-of-pocket spending on adalimumab
12 months
이차결과변수
결과변수측정값 설명시간 범위
Number of participants in the intervention arm who participated in an educational meeting with an academic detailer
6 months
Number of filled biosimilar prescriptions for other medications with biosimilar versions available, including ustekinumab, tocilizumab, and infliximab
12 months
Number of filled prescriptions for other brand-name disease-modifying medications that are FDA approved to treat 1 or more of the same indications as adalimumab, such as TNF-alpha inhibitors and interleukin inhibitors
12 months
Number of patients who fill 1 or more prescriptions for biosimilar adalimumab who subsequently switch back to originator biologic
12 months
참여 도우미
적격성 기준

연령대
어린이, 성인, 노인
참여 가능한 성별
전체
  • Wrote 7 or more adalimumab prescriptions that were filled by patients enrolled in research-eligible Humana Medicare Part D plans in the calendar year 2025

  • Retired
  • Not able to identify active clinical practice in the US (50 states plus Washington DC)
Brigham and Women's Hospital logo브리검 앤 위민스 병원
Humana Healthcare Research, Inc. logoHumana Healthcare Research, Inc.
연구 책임자
Benjamin Rome, 책임연구자, Assistant Professor of Medicine, Brigham and Women's Hospital
연락처 정보가 없습니다.
2 1개국에 임상시험 장소

Kentucky

Humana Healthcare Research, Inc., Louisville, Kentucky, 40202, United States

Massachusetts

Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States